Web Analytics

3 Latest Announced Rounds

  • $67,000,000
    Series A
    Biotechnology Research
    Apr 2nd, 2025
  • $10,000,000
    Seed

    2 Investors

    Software Development
    Apr 2nd, 2025
  • $5,200,000
    Series A

    3 Investors

    Technology, Information and Internet
    Apr 2nd, 2025
$1,676.17M Raised in 53 Funding Rounds in the past 7 Days - View All

Funding Round Profile

ProJenX

start up
United States - New York, NY
  • 03/11/2023
  • Series A
  • $15,000,000

ProJenX is a clinical-stage biotechnology company with novel, targeted, brain-penetrant therapies to address neurodegenerative diseases, with an initial focus on ALS. ProJenX was created out of a long-term research collaboration between Project ALS and Columbia University to rapidly develop and commercialize its lead therapy candidate, prosetin, for people with ALS. At the heart of ProJenX’s discoveries is an innovative, patient-specific, cell-based discovery platform that can be leveraged for the creation of additional transformative neuroscience medicines.


Related People

Stan AbelFounder

Stan Abel United States - New York, New York

N/A